| Date | Title | Description |
| 10.11.2015 | MiRagen Lands $41M for MicroRNA Drugs in Cancer, Fibrosis | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
MiRagen Therapeutics is now ready to move into clinical development, backed by a $41 million financing round that will support trials of a pair of drug candidates for fibrosis... |
| 10.11.2015 | miRagen Therapeutics Raises $41M in Series C Funding | miRagen Therapeutics, a Boulder, CO-based biopharmaceutical company developing innovative microRNA-based therapeutics, raised $41m in Series C funding.
The round was co-led by MRL Ventures and JAFCO Co., with participation from other invest... |
| 18.02.2015 | MiRagen raises $8.5 million for microRNA therapies that treat heart and blood disorders | The company’s most recent fundraise was last June when it raised $7 million. The company didn’t respond to calls about how this most recent funding round will be used.
Promoted
Clinical Care Capacity Planning
Learn how to manage clinical ca... |
| 26.06.2014 | MiRagen Therapeutics Raises $7M, Extends Deal with France’s Servier | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
MiRagen Therapeutics, a Boulder, CO-based drug discovery company focused on developing microRNA-targeting therapies for cardiovascular and muscle diseases, has extended its co... |
| 24.04.2012 | MiRagen Therapeutics Completes $20M Series B Financing | MiRagen Therapeutics, a Boulder, CO-based biopharmaceutical company developing innovative microRNA (miRNA)-based therapeutics primarily for the treatment of patients who suffer from cardiovascular and muscle disease, completed a $20m Series... |
| 24.04.2012 | miRagen Therapeutics Secures $20M Series B |
BOULDER, CO, Biopharmaceutical company developing innovative microRNA (miRNA)-based therapeutics primarily for the treatment of patients who suffer from cardiovascular and muscle disease, announced today the completion of a $20 million Se... |
| - | MiRagen raises $8.5 million for microRNA therapies that treat heart and blood disorders | Colorado-based MicroRNA upstart MiRagen Therapeutics just raised $8.5 million of a potential $20 million round, according to a regulatory filing. Its miRNA drugs are focused on correcting a number of cardiovascular, blood malignancies and f... |
